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ABSTRACT
The American Thoracic Society guidelines recommend long-acting b2-agonist (LABA)/long-acting mus-
carinic antagonist (LAMA) dual bronchodilation over LAMA or LABA monotherapy as maintenance
therapy for patients with chronic obstructive pulmonary disease suffering from dyspnea or exercise
intolerance. Previous studies, which included patients receiving background inhaled corticosteroids
(ICS), have shown the benefits of dual bronchodilation over monotherapy. This analysis aimed to con-
firm the benefits of LAMA/LABA over LAMA alone, without any confounding effects from ICS use. This
pooled post hoc analysis compared the efficacy of tiotropium/olodaterol with tiotropium alone in
patients from the TONADOVR and OTEMTOVR clinical trials who were not receiving ICS at study entry or
during the studies. We analyzed change from baseline in trough forced expiratory volume in 1 s
(FEV1), St. George’s Respiratory Questionnaire (SGRQ) score and Transition Dyspnea Index (TDI) score
in all patients, by Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage, baseline SGRQ
score, and Baseline Dyspnea Index score. In this analysis of 1596 patients, tiotropium/olodaterol
improved trough FEV1, SGRQ and TDI compared with tiotropium alone. The observed mean differen-
ces were: trough FEV1, 0.054L (95% confidence interval [CI] 0.036, 0.073; p< 0.001); SGRQ, 1.918
(95% CI 2.994, 0.843; p< 0.001); and TDI, 0.575 (95% CI 0.301, 0.848; p< 0.001). Similar improve-
ments were seen in each of the subgroup analyses. Tiotropium/olodaterol therapy significantly
improved lung function, symptoms and health status compared with tiotropium alone. In a population
free from ICS treatment, these data confirm the benefits of dual bronchodilation versus monotherapy.
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Plain language summary
It is recommended that most people with COPD begin treat-
ment with two types of inhaled medicine. These medicines are
known as LAMAs and LABAs, and they help to make breath-
ing easier. Doctors can prescribe these treatments alone or
together (LAMA/LABA). In the past, several studies have
shown that combining LAMAs with LABAs is better than giv-
ing either treatment alone. However, many patients in these
studies also received an inhaled steroid treatment in addition
to their LAMA and/or LABA therapy, which can make it
harder to interpret the study results. To help doctors decide
whether combined LAMA/LABA treatment is better than sin-
gle treatment, we looked at people with COPD who took
LAMA or combined LAMA/LABA treatment – without
inhaled steroids – as part of two large studies (TONADOVR
and OTEMTOVR ). We measured changes in how well the lungs
worked, patients’ health status, or their ability to breathe. After
12weeks, each of these outcomes was better in patients who
received LAMA/LABA than in patients who received LAMA
alone. These findings are similar to those from studies that
included patients receiving steroids in addition to the other
treatments. These results support recommendations to doctors
to prescribe combined LAMA/LABA treatment to their
patients with COPD, rather than LAMA alone.
A graphical abstract to accompany this manuscript is
included in the online supplement.
Introduction
The Global Initiative for Chronic Obstructive Lung
Disease (GOLD) strategy report recommends that patients
be treated with long-acting b2-agonists (LABA) or long-
acting muscarinic antagonists (LAMA) therapy as first-line
treatment, with dual bronchodilation recommended for
more symptomatic patients. Inhaled corticosteroids (ICS)
should be reserved for patients with high eosinophil
counts (>300 cells/mL) and with a history of frequent
exacerbations (2 moderate exacerbations or >1 severe
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exacerbation in the previous year) [1]. Furthermore, the
American Thoracic Society (ATS) recommends dual bron-
chodilation in patients with COPD who experience dys-
pnea or exercise intolerance [2]. The National Institute for
Health and Care Excellence (NICE) recommends dual
LAMA/LABA therapy in patients with COPD with no
indication of asthmatic features or corticosteroid respon-
siveness who remain breathless or have exacerbations des-
pite optimized non-pharmacologic management and use of
short-acting bronchodilators [3].
These recommendations are largely based on studies that
included patients on a range of background therapies [4–7],
including ICS use in a proportion of patients [4, 7]. Patients
who are prescribed ICS differ from those not given these
treatments and report more exacerbations of disease [8],
which can impact their health status. Hence, it cannot be
presumed that treatments are equally effective in patients
requiring and not requiring regular ICS.
To be confident that the guidance to use dual bronchodila-
tion in many COPD patients is applicable to those naïve to
ICS, we sought to determine if dual bronchodilation with
LAMAs/LABAs is more effective than a single bronchodilator
in patients with COPD unconfounded by ICS use. We per-
formed a pooled post hoc analysis of patients with COPD
from the TONADOVR 1&2 [4] and OTEMTOVR 1&2 [9] stud-
ies excluding around 44.5% of patients who were receiving
ICS from the original trial populations who were randomized
to receive tiotropium 5mg or tiotropium/olodaterol 5/5mg.
We assessed the impact of dual bronchodilation with tio-
tropium/olodaterol on lung function, health status and
symptoms versus tiotropium monotherapy, using a range of
endpoints including trough forced expiratory volume in 1 s
(FEV1), St. George’s Respiratory Questionnaire (SGRQ) total
score and Transition Dyspnea Index (TDI) focal score. We
also evaluated whether the baseline status of these endpoints
impacted patients’ responses to treatment.
Methods
The study designs and inclusion criteria of the 52-week
TONADO 1&2 (NCT01431274 and NCT01431287) and
12-week OTEMTO 1&2 (NCT01964352 and NCT02006732)
studies have previously been described [4, 9]. These replicate,
double-blind, parallel-group, active-controlled, multicenter,
randomized, Phase III studies assessed patients with moder-
ate-to-severe (OTEMTO) or moderate-to-very-severe
(TONADO) COPD, with a focus on lung function, health sta-
tus, and dyspnea severity [4, 9]. While OTEMTO included
placebo-controlled and comparator-controlled arms,
TONADO did not include a placebo-controlled arm [4, 9].
Patients
The current analysis includes patients with moderate-to-very-
severe COPD (GOLD stage 1–4) from the TONADO and
OTEMTO studies. At baseline, patients included in this ana-
lysis were receiving either no maintenance therapy, LABA
monotherapy, LAMA monotherapy or dual LAMA/LABA
bronchodilator therapy, and received either tiotropium mono-
therapy or tiotropium/olodaterol dual bronchodilation therapy
during the TONADO and OTEMTO clinical trials. Patients
who were on ICS were excluded from this analysis.
Treatments were administered once daily with the
RespimatVR inhaler (Boehringer Ingelheim, Ingelheim am
Rhein, Germany). Rescue medication (salbutamol [albu-
terol]) was provided as required for all study participants.
The studies included in this post hoc analysis were previ-
ously approved by the review boards of the relevant
national, regional or independent ethics committee or insti-
tutional review boards. These studies were conducted in
accordance with the Declaration of Helsinki and Good
Clinical Practice guidelines. Patients in these studies pro-
vided written informed consent.
Study endpoints and assessments
Change from baseline to Week 12 in trough FEV1, SGRQ
total score, and TDI focal score was calculated from pooled
data for all patients and subsets of these patients.
A mixed-effects model for repeated measures (MMRM)
was used to generate adjusted means of treatment effect,
including the fixed effects of treatment, study, planned test
day, treatment-by-test day interaction, baseline and baseline-
by-test day interaction, plus the random effect of patient.
The current analyses were conducted on the whole popula-
tion, GOLD 2 and 3 subgroups, Baseline Dyspnea Index
(BDI) 6 and >6 subgroups, and SGRQ<median
andmedian subgroups. Median SGRQ scores were selected
for this analysis to create reasonably sized subgroups.
Responder rates for these endpoints were also analyzed
using a logistic regression model that included the covariates
study and treatment. Responders for trough FEV1 (a change
of >100mL), SGRQ (a decrease of 4.0 points) and TDI
(an increase of 1.0 point versus baseline at the time of
analysis) were defined based on suggested minimum clinic-
ally important differences (MCID) [4, 10–12]. All p-values
included in this analysis are nominal.
Safety endpoints were assessed through the number of
adverse events (AEs) reported in the trials for the
pooled population.
Results
Baseline characteristics
Baseline characteristics were collected from 1596 patients
with moderate-to-very-severe COPD (GOLD stage 2–4) who
were not treated with ICS at baseline or during the study
period. The majority of patients (92.4%) were GOLD stage 2
or 3 (Table 1). At baseline, 1078 patients (67.5%) were main-
tenance naïve (not receiving LAMA, LABA or ICS), 299
(18.7%) were receiving LAMA monotherapy, 127 patients
(7.9%) were receiving LAMA/LABA therapy, and 92 (5.7%)
were receiving LABA monotherapy. Post-randomization,
825 patients (51.7%) received tiotropium and 771 patients
(48.3%) received tiotropium/olodaterol. Baseline
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characteristics were similar between patients randomized to
tiotropium or tiotropium/olodaterol (Table 1).
Efficacy at week 12
Trough FEV1
An increase of 0.141 ± 0.007 L in trough FEV1 from baseline
to 12weeks of treatment was noted for patients treated with
tiotropium/olodaterol; with an increase of 0.086 ± 0.007 L for
patients receiving tiotropium monotherapy. The adjusted
mean difference between tiotropium/olodaterol and tio-
tropium was 0.054 ± 0.010 L (95% confidence interval [CI]
0.036, 0.073; p< 0.001) (Figure 1(a)), with similar results
irrespective of baseline GOLD stage, SGRQ score or BDI
score (Figure 1(a,b)). For GOLD 4 patients, not included in
Figure 1 due to small sample size, an increase of
0.115 ± 0.016 L was noted for patients treated with tio-
tropium/olodaterol, with an increase of 0.057 ± 0.015 L for
patients receiving tiotropium monotherapy.
In terms of responders, of the 763 tiotropium/olodaterol-
treated patients, 451 (59.1%) achieved the MCID of
>100mL change in trough FEV1; of the 818 tiotropium-
treated patients, 342 (41.8%) achieved the MCID; odds ratio
2.012 (95% CI 1.647, 2.458; p< 0.001).
St. George’s Respiratory Questionnaire
A decrease (improvement) from baseline in SGRQ total score
was noted after 12weeks of treatment for patients treated with
tiotropium/olodaterol (–6.317±0.403 points) and tiotropium
monotherapy (–4.399±0.396 points). The adjusted mean
difference between tiotropium/olodaterol and tiotropium was
1.918±0.548 points (95% CI 2.994, 0.843; p< 0.001)
(Figure 2(a)). Similar results were shown in the subgroup ana-
lysis for GOLD 2 patients (Figure 2(a)) and when stratified by
baseline median SGRQ (43.1 points) and baseline BDI status
(p< 0.05) (Figure 2(b)). In the GOLD 3 subset of patients, the
improvement in SGRQ score did not reach statistical signifi-
cance (p¼ 0.054). For GOLD 4 patients, a change of
10.74 ±1.756 points was noted for patients treated with tio-
tropium/olodaterol, with a change of 7.948±1.692 points for
patients receiving tiotropium monotherapy.
For the responder analysis, of the 734 tiotropium/oloda-
terol-treated patients, 424 (57.8%) achieved the MCID of
4.0-point decrease in SGRQ score; of the 772 tiotropium-
treated patients, 377 (48.8%) achieved the MCID; odds ratio
1.439 (95% CI 1.173, 1.765; p< 0.001).
Transition Dyspnea Index
After 12weeks of treatment, the mean TDI score improved by
2.154± 0.100 points for patients treated with tiotropium/olo-
daterol and 1.579± 0.098 points with tiotropium monother-
apy. The improvement was significantly greater with
tiotropium/olodaterol compared with tiotropium (treatment
difference: 0.575± 0.140 points; 95% CI 0.301, 0.848;
p< 0.001) (Figure 3(a)). Similar results were seen in the sub-
group analyses by GOLD 2/3, SGRQ and BDI (Figure 3(a,b))
(p< 0.05). For GOLD 4 patients, an increase of 2.378± 0.384
points was noted for patients treated with tiotropium/oloda-
terol, with an increase of 1.234± 0.371 points for patients
receiving tiotropium monotherapy.
In terms of responders, of the 741 tiotropium/olodaterol-
treated patients, 449 (60.6%) achieved the MCID of 1.0 point;
of the 777 tiotropium-treated patients, 379 (48.8%) achieved the
MCID; odds ratio 1.642 (95% CI 1.337, 2.018; p< 0.001).
Safety
Table 2 shows a summary of AEs for the combined steroid-
free population. The proportion of patients with any AE was
similar between the two treatment arms and most AEs were
mild or moderate. In the tiotropium arm, 61.8% of patients
reported at least one AE versus 61.0% in the tiotropium/olo-
daterol arm. The proportion of patients with an investiga-
tor-defined drug-related AE was also similar between the
two treatment arms: 46 (5.6%) in the tiotropium arm and
49 (6.4%) in the tiotropium/olodaterol arm.
Discussion
This post hoc analysis of data from participants in the
TONADO and OTEMTO studies assessed whether dual
bronchodilation with tiotropium/olodaterol was superior to
tiotropium monotherapy, in a population of patients not
using ICS. After 12weeks, tiotropium/olodaterol provided
significantly greater improvements in trough FEV1, TDI,
and SGRQ versus tiotropium monotherapy in all patients
(p< 0.001) and in most subgroups analyzed (p< 0.05).
Additionally, more responders showing improvements
Table 1. This is currently in the middle of the introduction - please could it
be moved to the next page, closer to where it’s first cited.
Characteristic Tio (n¼ 825) T/O (n¼ 771)
Age, years 63.5 (8.4) 63.6 (8.7)
Male, n (%) 585 (70.9) 525 (68.1)
Smoking status, n (%)
Never smoked 0 (0.0) 0 (0.0)
Ex-smoker 463 (56.1) 399 (51.8)
Current smoker 362 (43.9) 372 (48.2)
Weight, kg 76.9 (19.2)a 75.1 (18.5)b
Pre-bronchodilator FEV1, L 1.318 (0.53) 1.296 (0.51)
Pre-bronchodilator FVC, L 2.795 (0.85) 2.770 (0.86)
Pre-bronchodilator FEV1/FVC, % 47.189 (11.88) 46.798 (11.26)
Baseline SGRQ score 42.4 (17.7)c 42.0 (17.2)d
Baseline BDI score 6.6 (2.2)e 6.7 (2.1)f
Baseline medication, n (%)
Treatment-naïve 560 (67.9) 518 (67.2)
LABA only 52 (6.3) 40 (5.2)
LAMA only 151 (18.3) 148 (19.2)
LAMAþ LABA 62 (7.5) 65 (8.4)
GOLD stage, n (%)
1 2 (0.2) 0 (0.0)
2 490 (59.4) 460 (59.7)
3 269 (32.6) 255 (33.1)
4 64 (7.8) 56 (7.3)
Data are mean (SD) unless otherwise stated.
a–fSome patient data were not available for each of the recorded outcomes:
an¼ 822, bn¼ 760, cn¼ 820, dn¼ 765, en¼ 808, fn¼ 765.
BDI, Baseline Dyspnea Index; FEV1, forced expiratory volume in 1 s; FVC, forced
vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease;
LABA, long-acting b2-agonist; LAMA, long-acting muscarinic antagonist; SD,
standard deviation; SGRQ, St. George’s Respiratory Questionnaire; T/O, tio-
tropium/olodaterol; Tio, tiotropium.
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greater than the MCID were identified in patients receiving
tiotropium/olodaterol than patients receiving tiotropium.
Taken together, these results support the recommended use
of dual bronchodilation with tiotropium/olodaterol over tio-
tropium monotherapy in stable COPD patients not receiv-
ing ICS.
These results are consistent with those of the primary
TONADO and OTEMTO studies, which included patients
receiving ICS in addition to study treatments. In TONADO
and OTEMTO, greater improvements in FEV1, SGRQ, and
TDI focal score were identified for patients treated with tio-
tropium/olodaterol after 24weeks and sustained to 52weeks
(TONADO), or after 12weeks (OTEMTO) compared with
either agent alone [4, 9]. This suggests that the benefits of
tiotropium/olodaterol therapy over the monotherapies are
seen regardless of ICS use.
The present analyses intended to compare tiotropium
versus tiotropium/olodaterol; due to the nature of this
pooled analysis, comparisons with olodaterol monotherapy
were not conducted.
The benefits of dual LAMA/LABA therapy versus mono-
therapies have been shown in other recent clinical trials.
The EMAX trial, for example, showed that the proportion of
responders was greater for all symptom outcomes in patients
randomized to receive dual bronchodilator therapy (umecli-
dinium/vilanterol) versus those treated with umeclidinium
or salmeterol [13]. Additionally, in these symptomatic, low
exacerbation-risk patients with COPD, dual bronchodilation
provided early and sustained improvements in lung function
and symptoms, with reduced probability of short-term
COPD worsening, compared with monotherapy [13]. In a
pooled analysis of 23 clinical studies, where 53.6% of
Figure 1. (a) Change in trough FEV1 at Week 12 from baseline; all patients and by GOLD status. (b) Change in trough FEV1 at Week 12 from baseline; by baseline
SGRQ and BDI status.
BDI, Baseline Dyspnea Index; CI, confidence interval; FEV1, forced expiratory volume in 1 second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; SE,
standard error; SGRQ, St. George’s Respiratory Questionnaire; T/O, tiotropium/olodaterol; Tio, tiotropium.
N numbers below bars, adjusted mean response within bars.
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patients were receiving ICS alongside their current therapies,
it was reported that combining LAMA/LABA therapies pro-
vided numerically better treatment outcomes than LAMA or
LABA monotherapies for FEV1, SGRQ, and TDI [14].
Similarly, in the SHINE study, superior improvements in
lung function were identified with dual bronchodilation
(indacaterol/glycopyrronium) versus patients who received
either indacaterol, glycopyrronium, tiotropium, or placebo
[15]. These results were not influenced by concurrent use of
ICS [15], adding weight to the argument that dual broncho-
dilation offers greater improvements compared with mono-
therapies, regardless of ICS use.
The results of the present analysis support the current
ATS and NICE guidance regarding bronchodilation of
patients with COPD [2, 3]. The ATS recommends LAMA/
LABA combination therapy over monotherapy for patients
who complain of dyspnea or exercise intolerance [2], while
NICE recommends dual LAMA/LABA for patients who
experience COPD symptoms despite optimized non-pharma-
cologic management and use of short-acting bronchodila-
tors [3].
Additionally, the current analysis of ICS-free patients
supports superior efficacy benefits in patients receiving
LAMA/LABA over LAMA monotherapy with comparable
safety profiles. Similar efficacy and safety results have
recently been published for patients who escalated their
treatment from LAMA to LAMA/LABA or in maintenance-
naïve patients when comparing LAMA to LAMA/LABA in a
pooled population that did not exclude patients taking ICS
[16, 17].
When determining pharmacologic treatment plans, we
should consider the general distribution of patients with
Figure 2. (a) Change in SGRQ at Week 12 from baseline; all patients and by GOLD status. (b) Change in SGRQ at Week 12 from baseline; by baseline SGRQ and
BDI status.
BDI, Baseline Dyspnea Index; CI, confidence interval; GOLD, Global Initiative for Chronic Obstructive Lung Disease; SE, standard error; SGRQ, St. George’s Respiratory
Questionnaire; T/O, tiotropium/olodaterol; Tio, tiotropium.
N numbers below bars, adjusted mean response within bars.
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COPD. The majority of patients with COPD initially fall
into GOLD groups A or B [18], and most experience symp-
toms such as breathlessness rather than frequent exacerba-
tions [19, 20]. Indeed, only a subgroup of COPD patients
are frequent exacerbators and should require treatment with
ICS [21, 22]. Therefore, studies such as this are important to
help determine optimal treatments for those not requiring
ICS. Taken together with the results of previous studies, the
Table 2. Adverse event profile.
Characteristic Tio (n¼ 825) T/O (n¼ 771)
Patients with any AE, n (%) 510 (61.8) 470 (61.0)
Patients with severe AEs, n (%) 80 (9.7) 73 (9.5)
Patients with investigator-defined drug-related AEs, n (%) 46 (5.6) 49 (6.4)
Patients with other significant AEs (according to ICH E3), n (%) 28 (3.4) 14 (1.8)
Patients with AEs leading to discontinuation of trial drug, n (%) 54 (6.5) 31 (4.0)
Patients with serious AEs, n (%) 99 (12.0) 77 (10.0)
Fatal 9 (1.1) 11 (1.4)
Life-threatening 1 (0.1) 1 (0.1)
Disability/incapacity 2 (0.2) 1 (0.1)
Requires hospitalization 87 (10.5) 64 (8.3)
Prolonged hospitalization 1 (0.1) 1 (0.01)
Other 12 (1.5) 6 (0.8)
A patient may be counted in more than one seriousness criterion. Percentages are calculated using total number of patients
per treatment as the denominator. MedDRA version used for reporting: 20.0.
AE, adverse event; ICH, International Council for Harmonization; MedDRA, Medical Dictionary for Regulatory Activities.
Figure 3. (a) Change in TDI at Week 12 from baseline; all patients and by GOLD status. (b) Change in TDI at Week 12 from baseline; by baseline SGRQ and
BDI status.
BDI, Baseline Dyspnea Index; CI, confidence interval; GOLD, Global Initiative for Chronic Obstructive Lung Disease; SE, standard error; SGRQ, St. George’s Respiratory
Questionnaire; T/O, tiotropium/olodaterol; TDI, Transition Dyspnea Index; Tio, tiotropium.
N numbers below bars, adjusted mean response within bars.
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present analyses confirm that dual LAMA/LABA therapy
provides greater improvements compared with monother-
apy, irrespective of ICS use.
The current analysis pools data from four clinical trials,
representing a large, clinically relevant patient population
and allowing analysis of patients with COPD who were not
using ICS at baseline. The patients included in this analysis
were generally balanced across the two treatment arms.
There was a potential imbalance in patients’ smoking status,
but we do not believe that this influences the results of the
present analysis. However, due to the post hoc nature of the
analysis, these results do not conform to the randomization
model of statistical inference, limiting the power for statis-
tical comparisons. Another limitation to this analysis is that
OTEMTO was only 12weeks in duration; however, in
TONADO, the changes in the primary endpoints were sus-
tained throughout the 52-week treatment period [4]. As no
adjustments for multiplicity were conducted in this analysis,
the p-values are nominal, not confirmatory.
This analysis confirms the benefits of dual bronchodila-
tion versus a single bronchodilator, in a population of
COPD patients unconfounded by ICS use. In this pooled
analysis of over 1500 steroid-free patients with COPD, opti-
mizing bronchodilator treatment with tiotropium/olodaterol
significantly improved lung function, symptoms and health
status compared with tiotropium alone (p< 0.001), with
similar results when assessed in GOLD 2 and 3 patients and
according to their baseline symptoms (SGRQ and BDI)
(p< 0.05). Overall, these data support GOLD recommenda-
tions of dual bronchodilator therapy without ICS to improve
breathlessness and health status, and are in line with recent
guidance from the ATS and NICE regarding use of dual
bronchodilator therapy as primary therapy for patients
with COPD.
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